{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:55Z","timestamp":1792896955063,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtha.2025.06.031","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:52:11Z","timestamp":1752681131000},"page":"3515-3526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events"],"prefix":"10.1016","volume":"23","author":[{"given":"Cosmo","family":"Godino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gaspardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Minerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Cera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Slavich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila Anna","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Nemola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Fattorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Della Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Margonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.031_bib1","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.031_bib2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.031_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.031_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.031_bib5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.031_bib6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2146\/ajhp110725","article-title":"Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient","volume":"69","author":"Miyares","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2025.06.031_bib7","author":"Annex"},{"key":"10.1016\/j.jtha.2025.06.031_bib8","author":"Annex"},{"key":"10.1016\/j.jtha.2025.06.031_bib9","author":"Annex"},{"key":"10.1016\/j.jtha.2025.06.031_bib10","author":"Annex"},{"key":"10.1016\/j.jtha.2025.06.031_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-0041-1723770","article-title":"direct oral anticoagulants plasma levels measurement: clinical usefulness from trials and real-world data","volume":"47","author":"Renon","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.06.031_bib16","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1253\/circj.CJ-18-0506","article-title":"Anti-Xa activity and event risk in patients with direct factor xa inhibitors initiated early after stroke","volume":"82","author":"Wada","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jtha.2025.06.031_bib17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00228-019-02693-2","article-title":"Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation","volume":"75","author":"Mikli\u010d","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.031_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jjcc.2016.11.013","article-title":"Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban","volume":"70","author":"Sakaguchi","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.jtha.2025.06.031_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MBC.0000000000000558","article-title":"The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate","volume":"27","author":"Chang","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2025.06.031_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.031_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12959-018-0183-3","article-title":"Rivaroxaban plasma levels in patients admitted for bleeding events: Insights from a prospective study","volume":"16","author":"Sennesael","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2025.06.031_bib22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.031_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jth.14457","article-title":"Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants","volume":"17","author":"Testa","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.031_bib24","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.031_bib25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/bloodadvances.2023012408","article-title":"Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study","volume":"8","author":"Testa","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.031_bib26","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/bloodadvances.2024013126","article-title":"More early bleeds associated with high baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study","volume":"8","author":"Palareti","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.031_bib27","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1097\/FJC.0000000000001038","article-title":"Direct oral anticoagulants plasma levels in patients with atrial fibrillation at the time of bleeding: a pilot prospective study","volume":"78","author":"\u0160kor\u0148ov\u00e1","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.031_bib28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00228-022-03280-8","article-title":"Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study","volume":"78","author":"Nos\u00e1\u013e","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.031_bib29","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.031_bib30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1160\/TH10-03-0204","article-title":"An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma","volume":"104","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.031_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/345138","article-title":"Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations","volume":"2015","author":"Douxfils","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jtha.2025.06.031_bib32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bjh.17470","article-title":"A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation","volume":"193","author":"Willekens","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.031_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2025.06.031_bib34","article-title":"Influence of direct oral anticoagulant levels and thrombin generation on postoperative bleeding [SONAR]: a nested case-control study","author":"Shaw","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.031_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.23736\/S0026-4806.21.07432-2","article-title":"Safety and efficacy of direct oral anticoagulants (DOACs) in very elderly patients (\u226585 years old) with non-valvular atrial fibrillation","volume":"114","author":"Rubino","year":"2023","journal-title":"Minerva Med"},{"key":"10.1016\/j.jtha.2025.06.031_bib36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0037-1607436","article-title":"Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy: clinical practice experience in a single institution and literature review","volume":"44","author":"Russo","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.06.031_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13658","article-title":"Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight","volume":"52","author":"Bodega","year":"2022","journal-title":"Eur J Clin Invest"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:12:16Z","timestamp":1778818336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625004209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1538783625004209"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.031","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}